Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lung Deposition of CHF5993 pMDI in Healthy, Asthmatic, and COPD Subjects
NCT02975843Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Nov 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of beclomethasone dipropionate, formoterol and glycopyrronium bromide in asthma and chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Intrapulmonary Lung deposition expressed as % of nominal dose. Started Nov 2016; status: completed.
02
Drugs
beclomethasone dipropionateformoterolglycopyrronium bromide
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02975843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02975843.